ArticleScientific reports2025
Developing a more accurate population frequency of Marfan syndrome from predicted pathogenic FBN1 variants in the gnomAD cohorts.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Identification of Novel Genetic Risk Variants Associated With Early-Onset Ischemic Stroke in Taiwan.Neurology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marfan syndrome is an autosomal dominantly (AD)-inherited disease that results from pathogenic variants in the Fibrillin 1 (FBN1) gene, and is characterised by tall stature, elongated limbs and digits, lens abnormalities and aortic root dilatation, aneurysms and dissection, but milder forms also occur. Radiological imaging suggests that Marfan syndrome affects between one in 3000 and 5000 of the population. The aim of this study was to determine the population frequency of Marfan syndrome from the number of predicted pathogenic FBN1 changes found in a normal database. FBN1 variants were downloaded from gnomAD v2.1.1 and annotated with ANNOVAR. The population frequency was determined from the number of pathogenic null and structural variants, and the number of predicted pathogenic missense changes classified by rarity and computational scores. This population frequency was then compared with the frequencies in the control subset, and from gnomAD variants assessed as Pathogenic or Likely pathogenic in the ClinVar or LOVD databases. Our strategy identified predicted pathogenic FBN1 variants in one in 416 individuals, which was confirmed in the control subset (one in 356, p NS). Predicted pathogenic variants were most common in East Asian people (one in 243, p < 0.0001) and least common in Ashkenazim (one in 5185, p = 0.0082). The population frequencies based on pathogenic variants in the ClinVar or LOVD databases were one in 718 and one in 1014 respectively. Null variants which are associated with aortic aneurysms affected only one in 8624. Thus, Marfan syndrome is more common than previously recognised. Emergency departments and cardiac clinics in particular should be aware of undiagnosed Marfan syndrome and its cardiac risks, but many of those affected still have a milder phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.